Skip to main content

Table 3 Multi-variable logistic regression models with hospitalizations as dependent variable, evaluating effect of ICS (N = 61 in all)

From: MAIT cell counts are associated with the risk of hospitalization in COPD

Independent variables

Level of effect

Regression coefficient

Lower CL 95%

Upper CL 95%

p-value

Model 1

 Intercept

n.a

4.988

2.176

7.800

0.001

 Baseline FEV1 (% predicted)

n.a

− 0.007

− 0.053

0.040

0.775

 MAIT cell count (× 106/L)

n.a

− 0.061

− 0.135

0.013

0.108

 GOLD 2017 group

1 (group A)

− 5.442

− 6.539

− 4.346

< 0.001

 GOLD 2017 group

2 (group B)

− 5.081

− 6.097

− 4.064

< 0.001

 GOLD 2017 group

3 (group C)

13.412

n.a

n.a

n.a

 ICS use (yes 1/no 0)

n.a

− 0.649

− 1.411

0.113

0.095

Model 2

 Intercept

n.a

3.562

0.400

6.724

0.027

 Baseline FEV1 (% predicted)

n.a

− 0.016

− 0.065

0.033

0.526

 CD38 + (% of MAIT cells)

n.a

0.221

0.076

0.367

0.003

 GOLD 2017 group

1 (group A)

− 5.530

− 6.644

− 4.417

 < 0.001

 GOLD 2017 group

2 (group B)

− 5.957

− 7.052

− 4.862

 < 0.001

 GOLD 2017 group

3 (group C)

14.571

n.a

n.a

n.a

 ICS use (yes 1/no 0)

n.a

− 0.815

− 1.737

0.108

0.084

Model 3

 Intercept

n.a

1.427

− 2.983

5.838

0.526

 Baseline FEV1 (% predicted)

n.a

0.009

− 0.053

0.070

0.782

 LAG-3 + (% of MAIT cells)

n.a

0.889

0.321

1.457

0.002

 GOLD 2017 group

1 (group A)

− 7.986

− 10.033

− 5.938

< 0.001

 GOLD 2017 group

2 (group B)

− 5.387

− 6.641

− 4.113

< 0.001

 GOLD 2017 group

3 (group C)

16.024

n.a

n.a

n.a

 ICS use (yes 1/no 0)

n.a

− 1.537

− 2.756

− 0.317

0.014

  1. CL confidence level, FEV1 forced expiratory volume in 1 s, GOLD Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticosteroids, LAG-3 lymphocyte-activation gene 3, MAIT mucosal-associated invariant T, n.a. not applicable